Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Nephros (NEPH) Shares Outstanding (Weighted Average) (2016 - 2025)

Nephros (NEPH) has 16 years of Shares Outstanding (Weighted Average) data on record, last reported at $10.6 million in Q3 2025.

  • For Q3 2025, Shares Outstanding (Weighted Average) rose 0.89% year-over-year to $10.6 million; the TTM value through Sep 2025 reached $10.6 million, up 0.89%, while the annual FY2024 figure was $10.5 million, 1.34% up from the prior year.
  • Shares Outstanding (Weighted Average) reached $10.6 million in Q3 2025 per NEPH's latest filing, roughly flat from $10.6 million in the prior quarter.
  • Across five years, Shares Outstanding (Weighted Average) topped out at $10.6 million in Q3 2025 and bottomed at $9.9 million in Q1 2021.
  • Average Shares Outstanding (Weighted Average) over 5 years is $10.3 million, with a median of $10.3 million recorded in 2022.
  • Peak YoY movement for Shares Outstanding (Weighted Average): grew 15.05% in 2021, then dropped 0.02% in 2023.
  • A 5-year view of Shares Outstanding (Weighted Average) shows it stood at $10.0 million in 2021, then grew by 2.79% to $10.3 million in 2022, then grew by 0.86% to $10.4 million in 2023, then increased by 1.34% to $10.5 million in 2024, then grew by 0.82% to $10.6 million in 2025.
  • Per Business Quant database, its latest 3 readings for Shares Outstanding (Weighted Average) were $10.6 million in Q3 2025, $10.6 million in Q2 2025, and $10.6 million in Q1 2025.